Skip to main content

Table 2 Baseline comparison of measured novel biomarkers in the CorLipid population by the presence of coronary syndrome

From: Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease

  All diabetic patients
(n = 316)
Diabetic patients with ACS
(N = 176)
Diabetic patients with CCS
(N = 140)
P-value
Clinical parameters,
Median (IQR = Q3-Q1)]*
    
 Acylcarnitine C4 41 (736) 40.6 (735) 42.5 (423) 0.87
 Acylcarnitine C18:2 58 (264) 54.9 (263) 61.3 (151) 0.20
 Acylcarnitine ratio C4/C18:2 0.72 (12.5) 0.76 (12.5) 0.69 (3.4) 0.41
 ApoB 84.5 (412) 87.2 (412) 81.1 (152) 0.53
 ApoA1 97.9 (193) 89.2 (185) 113 (168) < 0.01
 ΑpoB/ΑpoA1 ratio 0.79 (6.9) 0.84 (6.9) 0.70 (3.2) 0.02
 Ceramide C24:0 7.5 (32.7) 7.4 (28.7) 7.7 (32.7) 0.80
 Ceramide C24:1 3.2 (12.5) 3.4 (6.7) 3.1 (12.5) 0.08
 Ceramide ratio C24:1/C24:0 0.45 (1.76) 0.45 (1.76) 0.42 (1.72) 0.18
 Adiponectin 162 (215) 162 (207) 160 (214) 0.81
  1. Variables with p value < 0.05 were identified as significant variables and they are in bold
  2. *Median values and interquartile range (IQR = Q3–1) are provided for all those variables since they have non-normal distribution